Related Experiment Videos
Perfluoroctylbromide and hepatosplenic computed tomography. Preliminary clinical study
J N Bruneton1, M N Falewee, C Balu-Maestro
1Department of Radiology, Centre Antoine, Lacassagne, Nice, France.
Investigative Radiology
|September 1, 1988
Summary
Perfluorocytlbromide (PFOB) emulsion shows good tolerance as an intravenous contrast agent for CT imaging. A dose of 2 g/kg is recommended for liver enhancement, while 1 g/kg suffices for spleen enhancement.
Area of Science:
- Medical Imaging
- Radiology
- Contrast Agents
Background:
- Hepatosplenic CT imaging requires effective contrast agents for diagnostic accuracy.
- Perfluorocytlbromide (PFOB) is a potential candidate for intravenous contrast media.
Purpose of the Study:
- To evaluate the preliminary safety and efficacy of PFOB emulsion as an intravenous contrast agent for hepatosplenic CT imaging in humans.
- To determine the optimal diagnostic dose for liver and spleen enhancement.
Main Methods:
- Ten human patients were examined using PFOB emulsion at varying dosages (1 to 2 g/kg).
- Clinical and biochemical parameters were monitored to assess tolerance.
- CT imaging was performed to evaluate hepatosplenic enhancement.
Main Results:
- PFOB emulsion demonstrated good clinical and biochemical tolerance across all tested dosages.
- A dosage of at least 2 g/kg was found necessary for significant liver enhancement.
- A dosage of 1 g/kg was sufficient to achieve adequate splenic enhancement.
Conclusions:
- PFOB emulsion is a safe and well-tolerated intravenous contrast agent for hepatosplenic CT imaging.
- The diagnostic dose for liver enhancement with PFOB is approximately 2 g/kg.
- The diagnostic dose for spleen enhancement with PFOB is approximately 1 g/kg.